Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Fortschrittliche pharmazeutische Formulierung für gezielte therapeutische Intervention.
Dosierung
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Stärke
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Packungsgröße
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Form
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Quelle
European Medicines Agency
Sicherheitsprofil
Kontraindikationen
Nebenwirkungen
Scanne diesen QR-Code, um schnell auf diese Seite auf deinem Mobilgerät zuzugreifen.